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The QT interval and the corrected QT interval
The QT interval is a reflection of the duration of myo­
cardial depolarization and repolarization. It is defined as 
the time between the onset of the QRS complex and the 
end of the T wave as it returns to baseline, as measured 
on the electrocardiogram (Figure 1). The QT interval is 
strongly  dependent  on  heart  rate,  with  ‘normal’  rate­
corrected (QTc) values considered to be between 360 and 
460 ms [1­3]. QT interval prolongation or shortening has 
been shown to be associated with an increased risk for 
life­threatening  ventricular  arrhythmias  and  sudden 
cardiac death (SCD) in familial congenital syndromes of 
long  [4,5]  and  short  QT  duration  [6],  as  well  as  in 
population­based  samples  with  [7]  and  without  [8,9] 
underlying cardiac disease. For example, Moss et al. [4] 
demonstrated that each 10 ms increase in QTc interval 
contributes to about 5% exponential increase in risk of 
cardiac  events  in  patients  with  long  QT  syndrome 
(LQTS).  Furthermore,  both  cardiac  and  non­cardiac 
drugs  have  been  reported  to  prolong  QT  interval  and 
induce arrhythmia in patients who have a QTc interval 
length within the reference range [10,11].
The QTc interval is known to be influenced by genetic 
factors, with heritability estimates between 25% and 52% 
[12­14].  In  the  TwinsUK  study,  a  UK­based  sample  of 
mostly female twins of European ancestry, the propor­
tions of additive genetic influences have been estimated 
as 55% for resting heart rate, 60% for uncorrected QT 
interval, and 50% for QTc [15]. Until recently, research 
into genetic factors influencing QT interval was limited 
to candidate genes known to have a role in arrhythmo­
genesis,  on  the  basis  of  their  involvement  in  the  con­
genital  monogenic  diseases  LQTS  and  short  QT  syn­
drome [16­21]. However, rapid advances in biotechnology 
have now made genome­wide association (GWA) studies 
possible. In contrast to candidate gene studies in which 
genes are selected on the basis of known or suspected 
disease mechanisms, GWA studies have the potential to 
identify  loci  that  have  not  been  previously  targeted  as 
having a role in the trait or disease, thereby highlighting 
potentially novel biological pathways [22].
An early GWA study for QTc interval [23], based on 
selection  of  individuals  from  the  extreme  tails  of  the 
population­based QTc interval distribution, identified a 
common variant in the nitric oxide synthase 1 adaptor 
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© 2010 BioMed Central Ltdprotein (NOS1AP) gene region, and this has been consis­
tently  confirmed  in  later  studies  [24­32].  Further  more, 
variants in NOS1AP have since been associated with risk 
of SCD in two separate population­based cohorts [33,34] 
and in subjects with LQTS [35].
The NOS1AP variant has been estimated to explain up 
to only 1.5% of QTc variance [23] (Figure 2), suggesting 
the need for additional and larger GWA studies with the 
potential to detect additional common genetic variants, 
which are likely to be of more modest effect size. Recent 
efforts in this direction include meta­analyses of GWA 
studies  of  QT  interval  duration  in  population­based 
cohorts  by  a  number  of  consortia  [24­26];  these  have 
contributed many newly associated loci to this complex 
trait, and have suggested a cumulative effect of individual 
variants on QT interval. Notably, the QTGEN [25] and 
QTSCD [26] consortia found that common variants in a 
number of genes previously known to cause congenital 
LQTS (KCNQ1, KCNH2, KCNE1 and KCNJ2) and short 
QT syndrome (SCN5A), were among the most strongly 
associated  with  QT  interval  in  these  population­based 
cohorts  (Figure  2).  Significantly,  two  of  the  novel  loci 
con  tained  genes  with  established  electrophysiological 
func  tion (ATP1B1 and PLN). A third locus on 16q21 was 
near GINS3 and NDRG4, which are genes that have been 
associated  with  myocardial  repolarization  in  zebrafish 
experiments [36,37], but the remaining loci fell in or near 
genes  with  less  obvious  immediate  biological  explana­
tions.  These  loci  included  a  RING­type  zinc­finger 
protein of unknown function (RNF207), a DNA­binding 
protein thought to have a role in the regulation of TNFA 
expression and which is related to a hereditary motor and 
sensory neuropathy (LITAF), and a DNA base­excision 
and repair gene (LIG3).
QT interval risk model
Given that the heritability of QTc is estimated to be about 
50%, how much of this can be explained by the common 
variants discovered so far? Based on the results of the 
combined  analysis  of  the  top  hits  of  the  QTGEN  and 
QTSCD  consortia,  we  selected  the  single  nucleotide 
polymorphism (SNP) with strongest association in each 
of the regions (Table 1) and constructed the following 
risk model using these SNPs weighted by their estimated 
effects in the meta­analysis:
Rbeta = (1.70∙grs846111 + 3.27∙grs12143842 + 1.78∙grs10919071 + 
1.23∙grs12053903 + 1.53∙grs11970286 + 1.44∙grs4725982 + 1.62∙grs12296050 + 
1.34∙grs8049607 + 1.68∙grs37062 + 1.05∙grs2074518 + 1.10∙grs17779747)/1.61
where  gSNP  is  the  risk  allele  dosage  of  SNP,  which  is 
defined by: (P(0 risk alleles) × 0) + (P(1 risk allele) × 1) + 
(P(2 risk alleles) × 2); this might be a non­integer value 
when  the  SNP  is  imputed,  that  is,  it  is  not  genotyped 
itself but its genotype probabilities are estimated based 
on linkage disequilibrium with nearby genotyped SNPs. 
The risk allele is defined as the allele that increases the 
risk of QT interval prolongation, and hence it might be 
different from the coded allele (for example, the risk allele 
of rs12053903 in SCN5A is T and not the coded allele C; 
Table  1).  The  model  gives  more  weight  to  SNPs  with 
larger effect and is standardized in such a way that the 
risk score lies between 0 and 22, that is, the maximum 
number of risk alleles.
This  model  was  then  validated  in  an  independent 
sample of 2,838 twins from the TwinsUK cohort; part of 
this  sample  (n  =  1,048)  had  been  analyzed  in  a  GWA 
study on QTc interval [24]. We adjusted QT interval for 
the  effects  of  RR  interval,  age,  sex,  height,  body  mass 
index, hypertension and QT­interval­influencing drugs, 
and used the non­standardized residuals for the genetic 
analyses.  The  twin  cohort  consisted  of  2,144  dizygotic 
twins (that is, 1,072 pairs) and 694 singletons, including 
478 monozygotic twins of which the mean residual QTc 
interval of both twins was used to optimize information.
The  effect  of  the  risk  model  on  QTc  was  estimated 
using  linear  regression  while  correcting  the  standard 
error of the regression coefficient for the twin relations 
[38,39]. The risk model was highly significantly associated 
with QTc interval (P = 2.0 × 10­31) and explained 4.7% of 
the phenotypic variance. Figure 3 shows that the length 
of the QTc interval increases with increasing genetic risk 
score, meaning that a larger number of risk alleles indeed 
predicts a longer QTc interval. For instance, individuals 
with a high genetic risk score of 15, which roughly corres­
ponds to 15 (out of 22) risk alleles, have a QTc interval of 
422.4 ± 3.3 ms, which is, on average, 17.6 ms longer than 
individuals  with  a  low  risk  score  of  6  (mean  QTc  = 
404.8 ms).
Figure 1. The surface electrocardiogram (ECG). The ECG provides 
information on the electrical events occurring within the heart, and 
is obtained by placing electrodes on the surface of the body. The 
duration of the QT interval on the ECG is defined as the duration 
between the beginning of the QRS complex and the end of the 
T wave. It is a reflection of ventricular action potential duration, and 
represents the time during which the ventricles depolarize and 
repolarize.
RR interval R R
P T P T
Q
S
Q
S
QT interval
Jamshidi et al. Genome Medicine 2010, 2:35 
http://genomemedicine.com/content/2/5/35
Page 2 of 7Figure 2. Explained variance per risk gene for prolonging the QTc interval. The explained variance per risk gene is ordered along the x-axis 
according to year of discovery and decreasing explained variance. The green diamond represents the finding in the KORA cohort [23] (nGWA = 186, 
nGWA+replication = 6,612), the blue squares represent the findings of the QTGEN study [25] (n = 13,685), the red triangles those from the QTSCD study 
[26] (n = 15,854), and the orange circle the finding from the meta-analysis of the TwinsUK/Bright/DCCT-EDIC cohorts [24] (n = 3,558). GWA, 
genome-wide association.
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Table 1. Results of 11 single nucleotide polymorphisms selected for the risk model in the combined analysis of QTSCD 
and QTGEN
Locus  Chromosome  Variant  Coded allele  Beta  Standard error  P value
RNF207  1  rs846111  C  1.70  0.21  3.69 × 10-16
NOS1AP  1  rs12143842  T  3.27  0.17  1.88 × 10-78
ATP1B1  1  rs10919071  A  1.78  0.22  1.20 × 10-15
SCN5A  3  rs12053903  C  -1.23  0.12  1.0 × 10-14
PLN; C6orf204  6  rs11970286  T  1.53  0.15  2.35 × 10-24
KCNH2  7  rs4725982  T  1.44  0.16  5.0 × 10-16
KCNQ1  11  rs12296050  T  1.62  0.19  2.80 × 10-17
LITAF  16  rs8049607  T  1.34  0.17  5.78 × 10-15
NDRG4; CNOT1  16  rs37062  G  -1.68  0.16  3.0 × 10-25
LIG3  17  rs2074518  T  -1.05  0.12  6.0 × 10-12
KCNJ2  17  rs17779747  T  -1.10  0.16  6.02 × 10-12
The KCNE1 non-synonymous D85N variant rs1805128 (see also Figure 2) was not included in our risk score. It was genome-wide significant in the QTGEN study, but 
could not be confirmed in the QTSCD study and the combined analysis due to limited genotyping coverage in QTSCD.
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In summary, the QTc genetic risk model based on the 
effects of the 11 genome­wide significant SNPs identified 
in the combined analysis of QTGEN and QTSCD was 
strongly associated with QT interval in our independent 
cohort  consisting  of  2,838  twins  from  the  TwinsUK 
cohort. However, all these variants together explain only 
about 5% of the total variance in QTc, and hence about 
10% of the heritability of QTc [15].
There  are  a  number  of  possible  explanations  for  this 
[40,41]. First, GWA studies rely on the ‘common disease, 
common  variant’  hypothesis  [42],  which  suggests  that 
genetic influences on many common diseases will be at 
least partly attributable to a limited number of common 
allelic variants present in more than 10% of the popu  la  tion. 
As  discussed,  GWA  studies  have  successfully  identi  fied 
such variants for QTc interval [23­26]. However, to avoid 
false­positive findings, they have used extreme signifi  cance 
thresholds  to  reliably  identify  these  associa  tions, 
potentially missing many common variants of small effect 
that  did  not  reach  the  genome­wide  signifi  cance  level. 
Detection of these additional novel variants will require 
huge sample sizes. To this end, the three existing consortia 
[24­26] and additional studies recently merged into one 
QT Interval International GWAS Consortium (QT­IGC).
Second, many important disease­causing variants may in 
fact be rare (that is, <5% or even <1%) and are unlikely to 
be detected through the GWA approach [43]. These rare 
variants may exert relatively strong phenotypic effects in 
the individuals carrying them, and may be more valuable 
in  individualized  risk  stratification,  given  their  greater 
predictive value [41]. The current GWA studies lack power 
to identify such rare variants with modest effect sizes.
While GWA studies have identified several novel deter­
minants of QT interval, very few functional variants have 
been identified. There is increasing evidence that many of 
the functional variants that underlie associations in GWA 
studies exert their effects through gene regulation rather 
than changing gene products. Additional resequencing of 
the genomic region of interest may be needed to identify 
the  ‘causal’  variant  followed  by  subsequent  functional 
annotation studies to ascertain the clinical implications 
of  these  variants  on  arrhythmias  and  SCD.  Progress 
towards finding these causal variants will likely increase 
the amount of heritability that can be explained. Infor­
mation on lower frequency alleles emerging from projects 
such as the 1,000 Genomes project [44] and the Personal 
Genome Project [45] will be used to produce even more 
comprehensive  GWA  arrays,  and  will  facilitate  the 
investigation of the lower frequency variants without the 
need for de novo sequencing. The use of next­generation 
sequencing  platforms,  which  provide  high­volume 
sequence data with costs for resequencing exonic regions 
of the genome now approaching those for GWA studies, 
will also no doubt play a role in achieving this goal.
The problem of missing heritability may also be partially 
solved using an approach whereby many of the hits from a 
GWA  study  are  followed  up,  rather  than  the  current 
practice  of  carrying  out  meta­analyses  and  extensive 
follow­up of only the top ranked hits. This approach was 
successfully  employed  in  a  recent  GWA  study  of  celiac 
disease [46,47]. By taking advantage of the ever­decreasing 
price of genotyping, one might simultaneously follow up in 
a large replication sample, for example, 1,536 loci, a typical 
panel for one common platform, in a single experiment.
To  date,  the  primary  study  population  of  published 
GWA  studies  has  been  of  European  origin.  Therefore, 
there  is  also  a  need  to  extend  association  analyses  to 
diverse non­European populations to confirm association 
signals identified thus far, as well as to potentially identify 
novel association signals [48,49] and etiological pathways.
Analyzing  existing  QT  GWA  study  datasets  with 
computational tools and pathway databases rather than 
considering only genes or gene variants may well further 
increase our understanding of the genetic architecture of 
this complex trait. Future and existing QT GWA study 
results have and will continue to identify important and 
potentially novel biochemical pathways for patho  physio­
logy  and  therapeutics.  Results  have  already  pointed 
toward a greater emphasis on ion channels, which have 
long been known to be involved in congenital LQTS, and 
more recently to the nitric oxide pathway. Indeed a recent 
study found that SNPs in the NOS1AP gene modify the 
QT, prolonging effects of certain drugs [50].
Figure 3. Correlation between genetic risk score and QT interval. 
The bars show the distribution of the risk score classes (left axis). In 
pink, a plot of the risk score versus unstandardized QT residual is 
given, and the blue line shows the means of the unstandardized QT 
residual within risk score classes (right axis). Error bars represent the 
standard errors of the means.
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Page 4 of 7Newly  identified  risk  genes  can  therefore  potentially 
advance drug development by highlighting novel thera­
peutic  targets,  or  refocusing  existing  efforts  for  drug 
development to target, for example, the ion channel gene 
pathways. Furthermore, genetic profiling might advance 
drug development by identifying participants most likely 
to  benefit  from,  or  least  likely  to  experience  adverse 
effects of, a targeted therapeutic approach.
Due to the generally small effect sizes of the markers 
identified  through  GWA  studies,  much  of  the  genetic 
data generated will not be of great value in isolation, but 
should  rather  be  interpreted  within  the  context  of  a 
predictive score, ideally complemented with information 
on  non­genetic/environmental  risk  exposures,  to  allow 
targeted medical intervention before the onset of symp­
toms. The viability of this application might be limited, 
however,  because  the  currently  identified  genes  only 
explain a small proportion of the heritability. This reflects 
the complexity of translating markers identified through 
population studies into reliable predictors at an indivi­
dual level. The diagnostic utility of genetic profiling also 
appears to be limited in other common complex diseases 
and traits. For example, a 54­locus genetic profile for the 
highly heritable trait height could predict only 4 to 6% of 
variation  in  height  compared  with  40%  by  traditional 
predictions  based  on  parental  height  [51].  In  fact, 
although  GWA  studies  have  been  very  successful  in 
identi  fy  ing  specific  loci  and/or  genomic  regions  that 
contribute to QTc and many other phenotypes, there has 
been some disappointment that only a small proportion 
of the heritability of many conditions has been accounted 
for [52,53]. However, it is important to remember that 
the main goal of GWA studies has never been disease 
predic  tion, but rather the discovery of biological path­
ways underlying polygenic disease or traits.
Despite the problems of ‘missing heritability’, associated 
loci  identified  from  GWA  studies  can  yield,  and  are 
already yielding, important insights into disease etiology, 
as well as potential drug targets. In the context of QT 
interval, the novel implication of a biochemical pathway 
such  as  the  nitric  oxide  pathway  in  repolarization  and 
arrhythmogenesis has already led to the suggestion that it 
is no longer sufficient to focus on the electrical properties 
of the heart when attempting to link genetic variation to 
cardiac  arrhythmias.  Rather,  scientists  and  clinicians 
should  now  also  consider  electrical  remodeling  in  res­
ponse to environmental factors which can be controlled 
by the expression and activity of signaling molecules such 
as NOS1AP.
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